Mantalaris, Athanasios PhD

Biography:

Dr. Athanasios (Sakis) Mantalaris co-leads the Biomedical Systems Engineering Lab alongside Dr. Nicki Panoskaltsis. His expertise is in modelling of biological systems and bioprocesses with a focus on mammalian cell culture systems, stem cell bioprocessing and tissue engineering. He received his PhD in Chemical Engineering from the University of Rochester in the United States with a thesis entitled “Engineering a Human Ex Vivo Bone Marrow Mimicry”.

Dr. Mantalaris has published over 200 peer-reviewed manuscripts, is co-editor of the book “Advances in Tissue Engineering,” has authored numerous book chapters and holds several patents. In 2012, he was elected as Fellow of the American Institute for Medical & Biological Engineering, a recognition reserved only for the top 2% of biomedical engineers of this international society that has over 50,000 members. In 2013, Dr. Mantalaris was awarded the prestigious ERC Advanced Investigator Award. In 2015, He was awarded the Donald Prize by the Institution of Chemical Engineering (IChemE) for ‘for his work in bioprocess engineering with a particular focus on developing integrated modelling-experimental platforms for biological/biomedical systems‘

Research:

Dr. Mantalaris’ research and teaching emphasizes on delivering an interdisciplinary program on bioprocess engineering for the production of high-value products for precision healthcare applications. Research challenges in the following areas have been identified: 1) Continuous manufacturing; 2) New process analytical tools; 3) Single-use systems; 4) Process intensification to improve yields while lowering costs; 5) Improved process robustness and predictability through “quality by design”. In addition, BSEL will also focus on precision medicine challenges for the customization of decisions and practices tailored to the individual patient by use of patient-specific information (“-omics” technologies) and/or the application of patient/disease-specific therapies, including cell therapies. BSEL’s focus will be in three main areas: (1) precision anti-cancer in silico/in vitro/in vivotreatment platforms, (2) Cellular therapies, and (3) monoclonal antibody production technologies..

Background: